Analysts Set Expectations for Repligen FY2024 Earnings

Repligen Co. (NASDAQ:RGEN) – Leerink Partnrs issued their FY2024 earnings estimates for shares of Repligen in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst P. Souda expects that the biotechnology company will post earnings of $1.55 per share for the year. The consensus estimate for Repligen’s current full-year earnings is $1.44 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2024 earnings at $0.39 EPS, Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.80 EPS and FY2026 earnings at $2.47 EPS.

Several other brokerages have also recently issued reports on RGEN. JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Benchmark restated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Stephens reiterated an “overweight” rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. UBS Group reduced their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Price Performance

RGEN opened at $124.73 on Friday. The firm has a market cap of $6.99 billion, a price-to-earnings ratio of -337.10, a PEG ratio of 4.36 and a beta of 0.96. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The stock’s 50-day moving average price is $141.54 and its 200 day moving average price is $144.77. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. Repligen’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Resources Management Corp CT ADV purchased a new stake in shares of Repligen during the third quarter worth about $37,000. M&T Bank Corp grew its stake in Repligen by 5.9% in the 3rd quarter. M&T Bank Corp now owns 3,166 shares of the biotechnology company’s stock worth $471,000 after acquiring an additional 177 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Repligen in the 3rd quarter valued at $658,000. MML Investors Services LLC lifted its stake in shares of Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 89 shares during the period. Finally, Kensington Investment Counsel LLC boosted its holdings in shares of Repligen by 1.9% during the third quarter. Kensington Investment Counsel LLC now owns 10,041 shares of the biotechnology company’s stock worth $1,494,000 after purchasing an additional 184 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.